Quick Order

VEGF 183 / VEGF-A Antibody, Rabbit PAb, Antigen Affinity Purified

  • VEGF 183 / VEGF-A Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry
  • VEGF 183 / VEGF-A Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot
DatasheetReviewsRelated ProductsProtocols
Human VEGF-A Antibody Product Information
Immunogen:Recombinant Human VEGF 183 / VEGF-A protein (Catalog#10009-HNAB)
Clone ID:
Ig Type:Rabbit IgG
Concentration:
Endotoxin:
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:Produced in rabbits immunized with purified, recombinant Human VEGF 183 / VEGF-A (rh VEGF 183 / VEGF-A; Catalog#10009-HNAB; P15692-3; Met 1-Arg 209). VEGF 183 / VEGF-A specific IgG was purified by Human VEGF 183 / VEGF-A affinity chromatography.
Human VEGF-A Antibody WB Application Image
Human VEGF-A Antibody IHC Application Image
VEGF 183 / VEGF-A Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry
[Click to enlarge image]
Caption:
Immunochemical staining of human VEGF183 in human kidney with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).
Other VEGF-A Antibody Products
VEGF/VEGFA Background

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Human VEGF/VEGFA References
  • Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
  • Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
  • Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
  • Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14.
  • Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193.
  • Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.
  • Product nameProduct name
    Size / Price
    Catalog: 10009-RP02-50
    List Price: 
    Price:      (You Save: )

    Datasheet & Documentation

    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"